Company profile: Everest Medicines
1.1 - Company Overview
Company description
- Provider of novel pharmaceutical therapies, including VELSIPITY (etrasimod), an oral once-daily S1P modulator for moderately to severely active ulcerative colitis; Nefecon, an oral delayed-release budesonide for primary IgA nephropathy in adults; Xerava (eravacycline), an IV antibiotic for complicated intra-abdominal infections; Zetomipzomib for autoimmune diseases; EVER001 for renal diseases; and an mRNA platform for vaccines and therapies.
Products and services
- Nefecon®: An oral, delayed-release formulation of budesonide for treating primary immunoglobulin A nephropathy (IgAN) in adults
- VELSIPITY® (etrasimod): An oral, once-daily sphingosine 1-phosphate (S1P) receptor modulator for treating moderately to severely active ulcerative colitis
- Xerava® (eravacycline): An intravenous antibiotic for treating complicated intra-abdominal infections caused by gram-positive, gram-negative, and anaerobic pathogens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Everest Medicines
Ernexa
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ernexa company profile →
Alpheus Medical
HQ: United States
Website
- Description: Provider of a non-invasive sonodynamic therapy platform for solid body cancers that uses ultrasound to activate a cancer-targeting drug, including an SDT platform for outpatient treatment of recurrent high-grade gliomas and CV-01, an investigational drug-device using low-intensity, large-field ultrasound to target cancer cells across the brain hemisphere; CV-01 is in Phase 1 clinical trials for recurrent glioblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpheus Medical company profile →
IO Biotech
HQ: Denmark
Website
- Description: Provider of immune-modulating cancer therapies built on its T-win technology, activating T cells against tumor and immune-suppressive cells. Offers IO102-IO103 T-win vaccines targeting IDO and PD-L1, used with anti-PD-1 therapy for metastatic melanoma, and runs Phase 2/3 trials with pembrolizumab in melanoma, lung, head and neck, and bladder cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IO Biotech company profile →
Rakuten Medical
HQ: United States
Website
- Description: Provider of investigational cancer therapies based on the proprietary Alluminox photoimmunotherapy platform, which combines a drug with targeting moieties and a light-activating device using non-thermal illumination to selectively target cancer cells; includes ASP-1929, an Alluminox-developed drug with dye-conjugated targeting moieties, approved in Japan for treating certain cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rakuten Medical company profile →
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Everest Medicines
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Everest Medicines
2.2 - Growth funds investing in similar companies to Everest Medicines
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Everest Medicines
4.2 - Public trading comparable groups for Everest Medicines
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →